Well-differentiated neuroendocrine carcinoma of the lung

A case report

M. Colleoni, M. Di Bartolomeo, C. Patriarca, R. Buzzoni, E. Bajetta

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Well-differentiated neuroendocrine carcinoma (WDNC) of the lower respiratory tract displays clinical and radiologic features intermediate between carcinoids and small cell carcinoma and shares some biologic characteristics with both. We describe a case of WDNC resistant to three different treatments. The patient, a 42-year-old woman, received 2 cycles of chemotherapy before coming to our observation, including cyclophosphamide, adriamycin and vincristine, with progression of disease. We administered r-alpha-2a interferon for 2 months, but the patient showed clinical progression. Therefore, streptozotocin associated with epirubicin was utilized, but the patient died of disease progression after 4 cycles and 10 months from the first treatment. The case of WDNC described in this report showed an unusual aggressive clinical course and was refractory to conventional and unconventional treatments. The proper management for WDNC is still unknown. However, according to literature data, the chemotherapeutic schemes employed for small cell lung cancer represent the first treatment choice for WDNC. Further studies are needed to help define treatment strategies according to the biology of the tumor.

Original languageEnglish
Pages (from-to)282-284
Number of pages3
JournalTumori
Volume77
Issue number3
Publication statusPublished - 1991

Fingerprint

Neuroendocrine Carcinoma
Lung
Disease Progression
Therapeutics
Epirubicin
Small Cell Carcinoma
Small Cell Lung Carcinoma
Carcinoid Tumor
Vincristine
Streptozocin
Interferon-alpha
Respiratory System
Doxorubicin
Cyclophosphamide
Observation
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Cancer Research

Cite this

Well-differentiated neuroendocrine carcinoma of the lung : A case report. / Colleoni, M.; Di Bartolomeo, M.; Patriarca, C.; Buzzoni, R.; Bajetta, E.

In: Tumori, Vol. 77, No. 3, 1991, p. 282-284.

Research output: Contribution to journalArticle

@article{f6efe9e3ece44042b50cfb33a07f517f,
title = "Well-differentiated neuroendocrine carcinoma of the lung: A case report",
abstract = "Well-differentiated neuroendocrine carcinoma (WDNC) of the lower respiratory tract displays clinical and radiologic features intermediate between carcinoids and small cell carcinoma and shares some biologic characteristics with both. We describe a case of WDNC resistant to three different treatments. The patient, a 42-year-old woman, received 2 cycles of chemotherapy before coming to our observation, including cyclophosphamide, adriamycin and vincristine, with progression of disease. We administered r-alpha-2a interferon for 2 months, but the patient showed clinical progression. Therefore, streptozotocin associated with epirubicin was utilized, but the patient died of disease progression after 4 cycles and 10 months from the first treatment. The case of WDNC described in this report showed an unusual aggressive clinical course and was refractory to conventional and unconventional treatments. The proper management for WDNC is still unknown. However, according to literature data, the chemotherapeutic schemes employed for small cell lung cancer represent the first treatment choice for WDNC. Further studies are needed to help define treatment strategies according to the biology of the tumor.",
author = "M. Colleoni and {Di Bartolomeo}, M. and C. Patriarca and R. Buzzoni and E. Bajetta",
year = "1991",
language = "English",
volume = "77",
pages = "282--284",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Well-differentiated neuroendocrine carcinoma of the lung

T2 - A case report

AU - Colleoni, M.

AU - Di Bartolomeo, M.

AU - Patriarca, C.

AU - Buzzoni, R.

AU - Bajetta, E.

PY - 1991

Y1 - 1991

N2 - Well-differentiated neuroendocrine carcinoma (WDNC) of the lower respiratory tract displays clinical and radiologic features intermediate between carcinoids and small cell carcinoma and shares some biologic characteristics with both. We describe a case of WDNC resistant to three different treatments. The patient, a 42-year-old woman, received 2 cycles of chemotherapy before coming to our observation, including cyclophosphamide, adriamycin and vincristine, with progression of disease. We administered r-alpha-2a interferon for 2 months, but the patient showed clinical progression. Therefore, streptozotocin associated with epirubicin was utilized, but the patient died of disease progression after 4 cycles and 10 months from the first treatment. The case of WDNC described in this report showed an unusual aggressive clinical course and was refractory to conventional and unconventional treatments. The proper management for WDNC is still unknown. However, according to literature data, the chemotherapeutic schemes employed for small cell lung cancer represent the first treatment choice for WDNC. Further studies are needed to help define treatment strategies according to the biology of the tumor.

AB - Well-differentiated neuroendocrine carcinoma (WDNC) of the lower respiratory tract displays clinical and radiologic features intermediate between carcinoids and small cell carcinoma and shares some biologic characteristics with both. We describe a case of WDNC resistant to three different treatments. The patient, a 42-year-old woman, received 2 cycles of chemotherapy before coming to our observation, including cyclophosphamide, adriamycin and vincristine, with progression of disease. We administered r-alpha-2a interferon for 2 months, but the patient showed clinical progression. Therefore, streptozotocin associated with epirubicin was utilized, but the patient died of disease progression after 4 cycles and 10 months from the first treatment. The case of WDNC described in this report showed an unusual aggressive clinical course and was refractory to conventional and unconventional treatments. The proper management for WDNC is still unknown. However, according to literature data, the chemotherapeutic schemes employed for small cell lung cancer represent the first treatment choice for WDNC. Further studies are needed to help define treatment strategies according to the biology of the tumor.

UR - http://www.scopus.com/inward/record.url?scp=0025766070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025766070&partnerID=8YFLogxK

M3 - Article

VL - 77

SP - 282

EP - 284

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 3

ER -